Cargando…

Novel Inhibitor for Downstream Targeting of Transforming Growth Factor-β Signaling to Suppress Epithelial to Mesenchymal Transition and Cell Migration

Cancer metastasis accounts for most of the mortality associated with solid tumors. However, antimetastatic drugs are not available on the market. One of the important biological events leading to metastasis is the epithelial to mesenchymal transition (EMT) induced by cytokines, namely transforming g...

Descripción completa

Detalles Bibliográficos
Autores principales: Toma, Tsugumasa, Tateishi, Hiroshi, Kawakami, Kensaku, Ali, Taha F. S., Kamo, Masahiro, Monde, Kazuaki, Nakashima, Yuta, Fujita, Mikako, Otsuka, Masami
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9102712/
https://www.ncbi.nlm.nih.gov/pubmed/35563439
http://dx.doi.org/10.3390/ijms23095047
_version_ 1784707393267957760
author Toma, Tsugumasa
Tateishi, Hiroshi
Kawakami, Kensaku
Ali, Taha F. S.
Kamo, Masahiro
Monde, Kazuaki
Nakashima, Yuta
Fujita, Mikako
Otsuka, Masami
author_facet Toma, Tsugumasa
Tateishi, Hiroshi
Kawakami, Kensaku
Ali, Taha F. S.
Kamo, Masahiro
Monde, Kazuaki
Nakashima, Yuta
Fujita, Mikako
Otsuka, Masami
author_sort Toma, Tsugumasa
collection PubMed
description Cancer metastasis accounts for most of the mortality associated with solid tumors. However, antimetastatic drugs are not available on the market. One of the important biological events leading to metastasis is the epithelial to mesenchymal transition (EMT) induced by cytokines, namely transforming growth-factor-β (TGF-β). Although several classes of inhibitors targeting TGF-β and its receptor have been developed, they have shown profound clinical side effects. We focused on our synthetic compound, HPH-15, which has shown anti-fibrotic activity via the blockade of the TGF-β Smad-dependent signaling. In this study, 10 μM of HPH-15 was found to exhibit anti-cell migration and anti-EMT activities in non-small-cell lung cancer (NSCLC) cells. Although higher concentrations are required, the anti-EMT activity of HPH-15 has also been observed in 3D-cultured NSCLC cells. A mechanistic study showed that HPH-15 inhibits downstream TGF-β signaling. This downstream inhibition blocks the expression of cytokines such as TGF-β, leading to the next cycle of Smad-dependent and -independent signaling. HPH-15 has AMPK-activation activity, but a relationship between AMPK activation and anti-EMT/cell migration was not observed. Taken together, HPH-15 may lead to the development of antimetastatic drugs with a new mechanism of action.
format Online
Article
Text
id pubmed-9102712
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91027122022-05-14 Novel Inhibitor for Downstream Targeting of Transforming Growth Factor-β Signaling to Suppress Epithelial to Mesenchymal Transition and Cell Migration Toma, Tsugumasa Tateishi, Hiroshi Kawakami, Kensaku Ali, Taha F. S. Kamo, Masahiro Monde, Kazuaki Nakashima, Yuta Fujita, Mikako Otsuka, Masami Int J Mol Sci Article Cancer metastasis accounts for most of the mortality associated with solid tumors. However, antimetastatic drugs are not available on the market. One of the important biological events leading to metastasis is the epithelial to mesenchymal transition (EMT) induced by cytokines, namely transforming growth-factor-β (TGF-β). Although several classes of inhibitors targeting TGF-β and its receptor have been developed, they have shown profound clinical side effects. We focused on our synthetic compound, HPH-15, which has shown anti-fibrotic activity via the blockade of the TGF-β Smad-dependent signaling. In this study, 10 μM of HPH-15 was found to exhibit anti-cell migration and anti-EMT activities in non-small-cell lung cancer (NSCLC) cells. Although higher concentrations are required, the anti-EMT activity of HPH-15 has also been observed in 3D-cultured NSCLC cells. A mechanistic study showed that HPH-15 inhibits downstream TGF-β signaling. This downstream inhibition blocks the expression of cytokines such as TGF-β, leading to the next cycle of Smad-dependent and -independent signaling. HPH-15 has AMPK-activation activity, but a relationship between AMPK activation and anti-EMT/cell migration was not observed. Taken together, HPH-15 may lead to the development of antimetastatic drugs with a new mechanism of action. MDPI 2022-05-02 /pmc/articles/PMC9102712/ /pubmed/35563439 http://dx.doi.org/10.3390/ijms23095047 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Toma, Tsugumasa
Tateishi, Hiroshi
Kawakami, Kensaku
Ali, Taha F. S.
Kamo, Masahiro
Monde, Kazuaki
Nakashima, Yuta
Fujita, Mikako
Otsuka, Masami
Novel Inhibitor for Downstream Targeting of Transforming Growth Factor-β Signaling to Suppress Epithelial to Mesenchymal Transition and Cell Migration
title Novel Inhibitor for Downstream Targeting of Transforming Growth Factor-β Signaling to Suppress Epithelial to Mesenchymal Transition and Cell Migration
title_full Novel Inhibitor for Downstream Targeting of Transforming Growth Factor-β Signaling to Suppress Epithelial to Mesenchymal Transition and Cell Migration
title_fullStr Novel Inhibitor for Downstream Targeting of Transforming Growth Factor-β Signaling to Suppress Epithelial to Mesenchymal Transition and Cell Migration
title_full_unstemmed Novel Inhibitor for Downstream Targeting of Transforming Growth Factor-β Signaling to Suppress Epithelial to Mesenchymal Transition and Cell Migration
title_short Novel Inhibitor for Downstream Targeting of Transforming Growth Factor-β Signaling to Suppress Epithelial to Mesenchymal Transition and Cell Migration
title_sort novel inhibitor for downstream targeting of transforming growth factor-β signaling to suppress epithelial to mesenchymal transition and cell migration
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9102712/
https://www.ncbi.nlm.nih.gov/pubmed/35563439
http://dx.doi.org/10.3390/ijms23095047
work_keys_str_mv AT tomatsugumasa novelinhibitorfordownstreamtargetingoftransforminggrowthfactorbsignalingtosuppressepithelialtomesenchymaltransitionandcellmigration
AT tateishihiroshi novelinhibitorfordownstreamtargetingoftransforminggrowthfactorbsignalingtosuppressepithelialtomesenchymaltransitionandcellmigration
AT kawakamikensaku novelinhibitorfordownstreamtargetingoftransforminggrowthfactorbsignalingtosuppressepithelialtomesenchymaltransitionandcellmigration
AT alitahafs novelinhibitorfordownstreamtargetingoftransforminggrowthfactorbsignalingtosuppressepithelialtomesenchymaltransitionandcellmigration
AT kamomasahiro novelinhibitorfordownstreamtargetingoftransforminggrowthfactorbsignalingtosuppressepithelialtomesenchymaltransitionandcellmigration
AT mondekazuaki novelinhibitorfordownstreamtargetingoftransforminggrowthfactorbsignalingtosuppressepithelialtomesenchymaltransitionandcellmigration
AT nakashimayuta novelinhibitorfordownstreamtargetingoftransforminggrowthfactorbsignalingtosuppressepithelialtomesenchymaltransitionandcellmigration
AT fujitamikako novelinhibitorfordownstreamtargetingoftransforminggrowthfactorbsignalingtosuppressepithelialtomesenchymaltransitionandcellmigration
AT otsukamasami novelinhibitorfordownstreamtargetingoftransforminggrowthfactorbsignalingtosuppressepithelialtomesenchymaltransitionandcellmigration